Indan analogs of fenfluramine and norfenfluramine have reduced neurotoxic potential

Pharmacology Biochemistry and Behavior

Volumn 59, Issue 3, 1998, Pages 709-715

  Cozzi, Nicholas V ^a,b   Frescas, Stewart ^a   Marona Lewicka, Danuta ^a   Huang, Xuemei ^a,c   Nichols, David E ^a  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Anorectice; Catecholamine; Dr ug discrimination; Fenfluramine; Neurotoxic; Norfenfluramine; Seratonin; Synatosomes

Indexed keywords

1 (1,3 BENZODIOXOL 5 YL) N METHYL 2 BUTANAMINE; 5 TRIFLUOROMETHYL 2 AMINOINDAN; AMPHETAMINE; CATECHOLAMINE; FENFLURAMINE; INDAN DERIVATIVE; LYSERGIDE; N ETHYL 5 TRIFLUOROMETHYL 2 AMINOINDAN; NORFENFLURAMINE; PAROXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANOREXIA; ARTICLE; BRAIN SYNAPTOSOME; CATECHOLAMINE UPTAKE; CONTROLLED STUDY; DRUG DISCRIMINATION; DRUG SYNTHESIS; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN UPTAKE; STRUCTURE ACTIVITY RELATION;

ANIMALS; APPETITE DEPRESSANTS; BODY WEIGHT; BRAIN CHEMISTRY; DISCRIMINATION (PSYCHOLOGY); FENFLURAMINE; INDANS; MALE; NERVOUS SYSTEM DISEASES; NEUROTRANSMITTER UPTAKE INHIBITORS; NORFENFLURAMINE; PAROXETINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE; SEROTONIN; SYNAPTOSOMES;

ANIMALIA;

EID: 0032031651     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-3057(97)00557-1     Document Type: Article

References (41)

1. Appel N. M., Contrera J. F., De Souza E. B. Fenfluramine selectively and differentially decreases the density of serotonergic nerve terminals in rat brain. Evidence from immunocytochemical studies J. Pharmacol. Exp. Ther. 249:1989;928-943.
2. Battaglia G., Yeh S. Y., O'Hearn E., De Souza E. B. MDMA-induced neurotoxicity. Parameters of degeneration and recovery of brain serotonin neurons Pharmacol. Biochem. Behav. 29:1988;269-274.
3. Blundell J. Pharmacological approaches to appetite suppression. Trends Pharmacol. Sci. 12:1991;147-157.
4. Borroni E., Garattini S., Mennini T. Differences between d-fenfluramine and d-norfenfluramine in serotonin presynaptic mechanisms. J. Neurochem. 40:1983;891-893.
5. Caccia S., Anelli M., Ferrarese A., Fracasso C., Garattini S. Single- and multiple-dose kinetics of d-fenfluramine in rats given anorectic and toxic doses. Xenobiotica. 22:1992;217-226.
6. Colado M. I., Murray T. K., Green A. R. 5-HT loss in rat brain following 3,4-methylenedioxymethamphetamine (MDMA), p-chloroamphetamine and fenfluramine administration and effects of chlormethiazole and dizocilpine. Br. J. Pharmacol. 108:1993;583-589.
7. De Deurwaerdere P., Bonhomme N., Le Moal M., Spampinato U. d-Fenfluramine increases striatal extracellular dopamine in vivo independently of serotonergic terminals or dopamine uptake sites. J. Neurochem. 65:1995;1100-1108.
8. Douglas J. G., Munro J. F. Drug treatment of obesity. Pharmacol. Ther. 18:1982;351-373.
9. Farfel G. M., Seiden L. S. Role of hypothermia in the mechanism of protection against serotonergic toxicity. II. Experiments with methamphetamine, p-chloroamphetamine, fenfluramine, dizocilpine and dextromethorphan. J. Pharmacol. Exp. Ther. 272:1995;868-875.
10. Fuller R. W., Perry K. W., Baker J. C., Molloy B. B. 6-Chloro-2-aminotetralin, a rigid conformational analogue of 4-chloroamphetamine. Pharmacological properties of it and related compounds in rats Arch. Int. Pharmacodyn. Ther. 212:1974;141-153.
11. Fuller R. W., Wong D. T., Snoddy H. D., Bymaster F. P. Comparison of the effects of 6-chloro-2-aminotetralin and of ORG 6582, a related chloroamphetamine analog, on brain serotonin metabolism in rats. Biochem. Pharmacol. 26:1977;1333-1337.
12. Fuller R. W., Snoddy H. D., Robertson D. W. Mechanisms of effects of d-fenfluramine on brain serotonin metabolism in rats. Uptake inhibition vs. release Pharmacol. Biochem. Behav. 30:1988;715-721.
13. Fuxe K., Larnebo L.-O., Hamberger B., Ogren S.-O. On the in vivo and in vitro actions of fenfluramine and its derivatives on central monoamine neurons, especially 5-hydroxytryptamine neurons, and their relation to the anorectic activity of fenfluramine. Postgrad. Med. J. 51(Suppl. 1):1975;35-45.
14. Garattini S., Caccia S., Mennini T., Samanin R., Consolo S., Ladinsky H. Biochemical pharmacology of the anorectic drug fenfluramine. A review Curr. Med. Res. Opin. 1(Suppl. 6):1979;15-27.
15. Garattini S., Mennini T., Bendotti C., Invernizzi R., Samanin R. Neurochemical mechanism of action of drugs which modify feeding via the serotonergic system. Appetite. 7:1996;15-31.
16. Garattini S., Mennini T., Samanin R. Reduction of food intake by manipulation of central serotonin. Current experimental results Br. J. Psychiatry. 155:1989;41-51.
17. Glennon R. A., Young R., Hauck A. E., McKenney J. D. Structure-activity studies on amphetamine analogs using drug discrimination methodology. Pharmacol. Biochem. Behav. 21:1984;895-901.
18. 3H]5-hydroxytryptamine induced by d-fenfluramine in rat hippocampal synaptosomes. Eur. J. Pharmacol. 238:1993;9-17.
19. Gray E. G., Whittaker V. P. The isolation of nerve endings from brain. An electron-microscopic study of cell fragments derived by homogenization and centrifugation J. Anat. 96:1962;79-96.
20. Johnson M. P., Nichols D. E. Comparative serotonin neurotoxicity of stereoisomers of fenfluramine and norfenfluramine. Pharmacol. Biochem. Behav. 36:1990;105-109.
21. Johnson M. P., Nichols D. E. Combined administration of a nonneurotoxic 3,4-methylenedioxyamphetamine analogue with amphetamine produces serotonin neurotoxicity in rats. Neuropharmacology. 30:1991;819-822.
22. Johnson M. P., Frescas S. P., Oberlender R., Nichols D. E. Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan. Similarities to 3,4-(methylenedioxy)methamphetamine (MDMA) J. Med. Chem. 34:1991;1662-1668.
23. Kirby L. G., Kreiss D. S., Singh A., Lucki I. Effect of destruction of serotonergic neurons on basal and fenfluramine-induced serotonin release in striatum. Synapse. 20:1995;99-105.
24. Litchfield J. T. Jr., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
25. Marona-Lewicka D., Nichols D. E. Behavioral effects of the highly selective serotonin releasing agent 5-methoxy-6-methyl-2-aminoindan. Eur. J. Pharmacol. 258:1994;1-13.
26. Marona-Lewicka D., Rhee G.-S., Sprague J. E., Nichols D. E. Reinforcing effects of certain serotonin-releasing amphetamine derivatives Pharmacol. Biochem. Behav. 53:1996;99-105.
27. Mennini T., Garattini S., Caccia S. Anorectic effect of fenfluramine isomers and metabolites. Relationship between brain levels and in vitro potencies on serotonergic mechanisms Psychopharmacology (Berlin). 85:1985;111-114.
28. Murray T. K., Williams J. L., Misra A., Colado M. I., Green A. R. The spin trap reagent PBN attenuates degeneration of 5-HT neurons in rat brain induced by p-chloroamphetamine but not fenfluramine. Neuropharmacology. 35:1996;1615-1620.
29. Nichols D. E., Hoffman A. J., Oberlender R. A., Jacob P. III, Shulgin A. T. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine. Representatives of a new therapeutic class J. Med. Chem. 29:1986;2009-2015.
30. Nichols D. E., Brewster W. K., Johnson M. P., Oberlender R., Riggs R. M. Nonneurotoxic tetralin and indan analogues of 3,4-(methylenedioxy)amphetamine (MDA). J. Med. Chem. 33:1990;703-710.
31. Nichols D. E., Johnson M. P., Oberlender R. 5-Iodo-2-aminoindan, a nonneurotoxic analogue of p-iodoamphetamine. Pharmacol. Biochem. Behav. 38:1991;135-139.
32. Nichols D. E., Oberlender R. Structure-activity relationships of MDMA-like substances. Asghar K., De Souza E. NIDA Research Monograph 94. Pharmacology and Toxicology of Amphetamine and related designer drugs. 1989;1-29 DHHS Publication (ADM) 89-1640, Washington, DC.
33. Oberlender R., Nichols D. E. Drug discrimination studies with MDMA and amphetamine. Psychopharmacology (Berlin). 95:1988;71-76.
34. Oberlender R., Nichols D. E. Structural variation and (+)-amphetamine-like discriminative stimulus properties. Pharmacol. Biochem. Behav. 38:1991;581-586.
35. Oluyomi A. O., Gibson E. L., Barnfield A. M. C., Curzon G. d-Fenfluramine and d-norfenfluramine hypophagias do not require increased hypothalamic 5-hydroxytryptamine release. Eur. J. Pharmacol. 264:1994;111-115.
36. Pinder R. M., Brogden R. N., Sawyer P. R., Speight T. M., Avery G. S. Fenfluramine. A review of its pharmacological properties and therapeutic efficacy in obesity Drugs. 10:1975;241-323.
37. Ricaurte G. A., Molliver M. E., Martello M. B., Katz J. L., Wilson M. A., Martello A. L. Dexfenfluramine neurotoxicity in brains of nonhuman primates. Lancet. 338:1991;1487-1488.
38. Rowland N. E., Carlton J. Neurobiology of an anorectic drug. Fenfluramine Prog. Neurobiol. 27:1986;13-62.
39. Sotelo C. Immunohistochemical study of short- and long-term effects of DL-fenfluramine on the serotonergic innervation on the rat hippocampal formation. Brain Res. 541:1991;309-326.
40. Trulson M. E., Jacobs B. L. Behavioral evidence for the rapid release of CNS serotonin by PCA and fenfluramine. Eur. J. Pharmacol. 36:1976;149-154.
41. Westphalen R. I., Dodd P. R. The regeneration of d,l-fenfluramine-destroyed serotonergic nerve terminals. Eur. J. Pharmacol. 238:1993;399-402.